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Abstract
Background: Focal lesions to the articular cartilage in the knee might have demolishing consequences to the knee.
There exists a wide range of possible surgical procedures targeting these injuries, however no significant differences
have been found between these procedures. This may support that the improvement is a result of rehabilitation,
and not the surgery itself. Arthroscopic microfracture (MF) treatment has gained popularity, and has become the
treatment of choice in patients with knee cartilage defects globally. In this study we want to increase knowledge,
both clinical and economic, about arthroscopic microfracture (AF) compared to arthroscopic debridement (AD) and
physical rehabilitation both in the short run, and in the long run.
Methods/Design: To compare arthroscopic microfracture with arthroscopic debridement and physiotherapy for
the treatment of focal cartilage lesions in the knee, a long-term, double-blinded, randomized controlled multicenter
trial will be conducted. A total of 114 men and non-pregnant women with a symptomatic focal full thickness
cartilage lesion in the knee less than 2 cm2 will be included in the study. The two treatment allocations will receive
identical rehabilitation, which is made up of 3 phases: accommodation, rehabilitation and return to activity. Follow
up is 24 months, where all will be invited to participate in late follow ups after 5 and 10 years.
The Knee Injury and Osteoarthritis Outcome Score (KOOS) knee-related quality of life (QoL) subscore is the primary
endpoint. Clinical parameters, questionnaires and radiologic modalities (Magnetic Resonance Imaging (MRI) and x-
ray) will be used as secondary endpoints.
Discussion: This is an ongoing multicenter study with a high level of evidence to compare arthroscopic
microfracture with arthroscopic debridement and physiotherapy for the treatment of isolated symptomatic full
thickness cartilage lesions in the knee joint.
Trial registration: ClinicalTrials.gov ID: NCT02637505 (December 15, 2015).
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Background
Articular cartilage is highly specialized tissue in joints,
with main functions to provide lubrication to the joint
and load shearing. Since the hyaline cartilage covering
the articular surface is devoid of blood vessels, lymphatic
drainage and nerves, very limited intrinsic healing capacity
exist [1–3]. Focal lesions to the articular cartilage in the
knee might have demolishing consequences to the knee
both in the short term and in the long term, due to the
predisposition of early onset osteoarthritis. With a preva-
lence of 12 % in young adults, focal cartilage lesions are
common [4]. Musculoskeletal disorders (MSDs) are the
most common occupational disease in the European
Union. Workers in all sectors and occupations can be
affected, and this may have a major impact both socially
and not least financially [5–8]. With this in mind, treat-
ment of symptomatic articular cartilage lesions is of great
interest to those who prevent and treat MSDs, as well as
the patient and the society [3, 9, 10].
All types of articular cartilage repair procedures aim to
repair cartilage whilst keeping options open for alterna-
tive treatments in the long term. The most common
surgical interventions are arthroscopic debridement,
bone marrow techniques with or without augmentation
with stem cells (including microfracture and autologous
matrix-induced chondrogenesis), osteochondral trans-
plantation (autografts and allografts), cell based repairs
(autologous chondrocyte implantation (ACI) and autolo-
gous mesenchymal stem cell transplant [11–13].
Arthroscopic debridement (AD) focusses on removing
loose articular flaps and fibrous tissue to the subchon-
dral bone [12]. Arthroscopic microfracture (AM) in-
cludes an AD procedure followed by drilling holes
(micofractures) through the subchondral bone using an
awl. This generates a blood clot (called a super-clot)
which becomes fibrocartilage over time and fills the
articular cartilage defect [12]. Improved knee function
have been reported in some studies [14], but they have
been criticized for weakness in methodology [15].
None of the various options for focal cartilage injuries
have been able to demonstrate a superior outcome when
compared to each other in randomized controlled trials,
suggesting that the strict post-operative rehabilitation
common for all techniques are more important to the
clinical improvement than the cartilage surgery itself
[16, 17].
Due to its minimally invasive approach, technical sim-
plicity and low costs, microfracture treatment has gained
popularity over the past decades, and has become the
treatment of choice in patients with knee cartilage defects
[18–23]. Microfracture is most likely not effective for
larger lesions [22, 24–26], and is currently recommended
for lesions below 2–4 cm2 [27–30]. Meta-analysis and sys-
tematic reviews have required well-designed, long-term,
multicenter studies to evaluate clinical outcomes of
microfracture with the use of a “no treatment” group as
a control group to increase knowledge, both clinical
and economic, about arthroscopic microfracture com-
pared to arthroscopic debridement in the short and
long run [10, 25, 26, 31, 32].
Purpose
Comparing arthroscopic microfracture (AM) with arthro-
scopic debridement (AD) in patients with symptomatic
full thickness knee cartilage defects less than 2 cm2 in the
knee joint is the purpose of this study. The aims will be
differences both in regard of subjective and objective vari-
ables at predefined times up to 24 months follow up.
Methods and design
The study emanates from “The Norwegian Cartilage Pro-
ject” (NCP). The NCP is a Norwegian project organization
with a goal of improving the treatment of injured articular
cartilage in the knee through five studies. The study proto-
col is written in collaboration with the authors behind the
already published study protocol regarding ACI and
debridement [33].
This multicenter study with 2 treatment arms (AM
and AD) is designed as a prospective, randomized,
double-blinded parallel study, see Fig. 1. The study
will be conducted at Norwegian hospitals including
Kristiansund Hospital, Haukeland University Hospital,
Ålesund Hospital, Diakonhjemmet Hospital, Haraldsplass
Deaconess Hospital, Oslo University Hospital – Ullevål
and Akershus University Hospital. Each hospital will have
a member of the NCP group as a local coordinator. The
sponsor of the study is Akershus University Hospital, with
sponsor representative professor Asbjørn Årøen.
Inclusion, treatment and follow-up of the patients will
be done at the orthopedic clinic at each of the above
mentioned hospitals. To secure double blinding at the
24 months follow up, the control will be performed by
an external reviewer connected to the NCP group. Fol-
low up is 24 months, but all will be invited to controls
at 5 and 10 years respectively.
Participants
A total of 114 non-pregnant women and men with the age
between 18-50 years old will be enrolled in the study, with
a cartilage defect up to 2 cm2 in the femoral condyles or
trochlea. By using a Lysholm score less than 75 [34], we
only include symptomatic defects in the study. Included
patients will have normal alignment (varus or valgus less
than 5° measured clinically and if uncertainty, on hip-
knee-ankle (HKA) angle images), normal range of motion
(ROM) (minimum 5–105°), a stable knee with no sign of
radiologically osteoarthritis [35] obtained with the Syna-
Flex X-ray positioning frame [36]. The inclusion criteria
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are based on Steadman et al, Saris et al and Ulstein et al
[22, 37, 38]. Prior to inclusion, written informed consent
will be obtained from all subjects.
All patients will, prior to inclucion, be assessed clinically
and radiologically. Using the International Cartilage Repair
Society (ICRS) grading system of cartilage defects, the de-
fect will be verified arthroscopically as a grade 3 or 4 [39].
Peroperatively arthroscopic findings such as inappropriate
size of the lesion, osteoarthritis or less than 50 % normal
meniscus will lead to preoperatively exclusion [40]. The
operating surgeon will perform definitive inclusion of the
patient in the study. According to the standard at the
local hospital, excluded patients will receive appropriate
treatment.
Systemic arthritis, osteoarthritis, pregnancy, language
barriers, severe obesity (body mass index > 30), co-
morbidities that may influence surgery or rehabilitation,
alcohol, substance or drug abuse, inability to complete
questionnaires or rehabilitation and psychiatric disorders
are exclusion criteria, see Table 1. Previous surgery to
the cartilage defects except debridement and fixation of
osteochondritis dissecans lesions are also exclusion cri-
teria. Previous alignment procedures, cruciate ligament
reconstruction and meniscus surgery are not criteria for
exclusion. Those who withdraw during the trials or de-
clining enrollment will be treated according to the
standard of care.
Blinding and randomization
The study is designed as a double blinded study. As long
as the trial lasts, the patients will not verbally nor writ-
ten be informed which treatment is given to them. The
operating surgeon will not be blinded, but will not be in-
volved in the follow ups. Doctors involved in follow ups
will be blinded for the given treatment. When patients
are completing the questionnaires during follow ups, the
case report forms (CRF) will not contain any informa-
tion of the given treatment. The follow up at 24 months
Fig. 1 Study flow chart
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will be performed at each of the hospitals by an external
reviewer connected to the NCP group to secure double
blinding at 24 months follow up. The analysis of X-rays
after 24 months will be done by an orthopaedic surgeon
and a study radiologist, both blinded for the given treat-
ment. The MRI at 24 months will be analyzed by the
same blinded study radiologist.
By using a computer generator (randomization.com),
the 114 participants will be randomized in blocks of six-
eight (1:1) according to treatment allocations. All included
participants will be given a number from 1 to 114 on in-
clusion. Concealed in opaque numerically marked enve-
lopes, randomization will be printed in faded text. An
employee at Kristiansund Hospital, not involved in the
study, will administer the printing and concealing. The
randomization will be done in the operation room during
surgery, after the lesion has been graded and measured by
the operating surgeon (see section “Operative procedure”).
Arthroscopic procedure
No tourniquet is used. Three standard incisions are
made. The procedure starts with a diagnostic arthro-
scopic examination to verify that the inclusion criteria
are present. Any other necessary procedures (plica, me-
niscus, removal of loose bodies) are performed. Removal
of lose and marginally attached cartilage is then done.
Thereafter, the cartilage lesion is classified according to
the ICRS classification, and measured using a standard
4-mm arthroscopic probe [39, 40]. The randomization is
performed at the end of the arthroscopy (see section
“Blinding and randomization) and the lesion will either
undergo arthroscopic debridement (AD) or arthroscopic
microfracture (AM).
Arthroscopic debridement
The lesion is stabilized, debriding all loose or marginally
attached cartilage from the surrounding rim to form a
stable edge of healthy cartilage around the defect using a
ring curette, where cartilage slops down to the defect.
Arthroscopic microfracture
The cartilage is cut sharp forming a rim of 90°. The calci-
fied layer is removed using a curette before an arthroscopic
awl is used to perform multiple holes (“microfractures”)
from the periphery towards the center. The microfractures
are 3–4 mm apart and 2–4 mm deep into the subchondral
bone. The correct and successful technique is confirmed
by direct observation of marrow fat droplets exiting the
microfracture as the fluid pump is reduced.
The instruments are removed and the incisions are
sutured. Since local anesthetics may have a harmful ef-
fect on cartilage, intra-articular local anesthetics will not
be used [41–43]. These surgical principles follow the
techniques by Steadman and Mithoefer [24, 44–46].
Before study start, all surgeons will be given proper
training in the arthroscopic study procedure.
Post-operative protocol
Identical postoperative care will be given, usually with
hospital admission up to 4 days. If there is a risk of
thromboembolic disease, anti-thrombotic prophylaxis is
given. Prophylactic antibiotic is not given. Up to 2 weeks
of sick leave after the operation is given all participants.
Any complications that should occur will be managed in
a prompt manner by the involved departments.
Rehabilitation protocol
All patients will be subjected to the same postopera-
tive rehabilitation protocol, based on the work by
Wondrasch et al [17]. The rehabilitation program will
be headed by a designated study physiotherapist along
with the patient’s local physiotherapist. The rehabilita-
tion protocol involves three phases: accommodation,
rehabilitation and return to activity, and is identical to
the rehabilitation protocol in the previous mentioned
ACI study [33], see Table 2.
A designated hospital physiotherapist and the surgeon
will on the first postoperative day instruct the patients in
range of motion exercises and gait training according to
Phase 1. Within two weeks of surgery, the patient is seen
by a local physiotherapist, who will supervise the rehabili-
tation program in liaison with the study physiotherapist.
The rehabilitation program includes both active re-
habilitation and patient education, and consists primarily
of knee/hip progressive resistance, neuromuscular training
and cardiovascular resistance, including plyometric exer-
cises and balance. During the physiotherapy, the patients
will be explained how to perform the exercises and why
they are important, adjusted to pain or other symptoms.
All patients are asked to use training diaries to provide
information about the training habits. Additionally, every
second week patients are asked to respond to an online
survey consisting of 4 questions, all with both predefined
answers (closed answers) and open answers available.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
-Age 18–50 years old
-Symptomatic cartilage defect
-Lysholm score < 75
-Defect size less than 2 cm2
-Lesion graded ICRS 3–4
- > 50 % intact meniscus
-Stable knee







- Obesity (BMI > 30)
- Comorbidities that may influence
surgery or rehabilitation
- Serious alcohol or drug abuse
- Inability to complete questionnaires
or rehabilitation
- Malalignment > 5°
- Earlier surgery to the chondral defect
excluding OCD surgery
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The training dairy will be continued till the end of the
project (24 months), while the online survey continues
as long as the patients are under supervision of a
physiotherapist.
1st phase - Accomodation:
During admission in hospital, the leg is placed in a
continunous passive motion (CPM) machine as
tolerated, aiming to achieve 30–70° on the first
postoperative day. The CPM should be used up to
6–8 h every 24 h during the hospital stay.
For the first two weeks, only touch-down weight-
bearing using crutches is allowed. The patients are
encouraged to continue range of motion exercises,
existing of 500 knee extensions/flexions three times a
day, after discharge from hospital. Each patient should
be scheduled to 2 to 3 supervised physical therapy
sessions. When the wound is healed, swimming is
allowed.
Passing two weeks, weight-bearing as tolerated is
carefully introduced, and gradually increased up to full
weight-bearing. When the patient walks normal with
limping, crutches are not needed.
2nd phase - Rehabilitation:
The patients perform 1–2 unsupervised training sessions
per week, and attend at least 2 supervised physical
therapy sessions. Exercises are performed with the
uninjured and injured limb. Walking with increasing
distances is encouraged, and when full weight-bearing is
achieved, cross-country skiing can be allowed.
3rd phase – Return to activity/sport:
The patients perform unsupervised resistance training
for a minimum of 2 and a maximum of 4 sessions per
week, and attend at least 1 supervised physical
therapy sessions per week. According to the goals for
each patient, this phase is individualized. If return to
sport is planned, sport-specific activities are included
as functional progressions in the rehabilitation
protocol.
Outcome measures
Outcome measures will be the same as the endpoints in
an earlier mentioned RCT coming from the same NCP
group [33], enabling a direct comparison in outcome.
Demographics
Age, gender, nationality, social status, work status, use
of medication, prior medical history height in cm,
weight in kg, Body Mass Index (BMI) and injury mech-
anism (if any) are collected at inclusion.
Endpoints
The Knee Injury and Osteoarthritis Outcome Score
(KOOS) knee-related quality of life (QoL) subscore is
the primary endpoint. Validated to use in cartilage
research studies, KOOS is a patient reported outcome
measure [47], and will enable comparison of our results
with other knee cartilage studies. At 24 months follow
up, the difference in KOOS QoL subscore in the AM
group compared to the AD group is the primary aim.
No interim analysis is planned.
Clinical parameters, questionnaires and radiologic
modalities will be used as secondary endpoints at
predefined times at 3 months (±2 weeks), 6 months
(±4 weeks), 12 months (±6 weeks) and 24 months
(±8 weeks). They include range of motion (ROM) mea-
sured with a goniometer, visual analogue scale (VAS),
all KOOS subscores except knee-related QoL, Tegner
score, Lysholm score and EQ-5D. The difference be-
tween the two treatment groups and within the group
will be the secondary aims. Information about work
(return to work), physical activity and return to sport
will also be collected.
Additionally, at the follow up after 24 months, a hop
test validated by Reid [48], standing radiographs and
MRI will be done. All participants will be invited to late
follow ups after 5 and 10 years respectively.
Table 2 Rehabilitation protocol (identical for both groups)
Rehabilitation phases Objectives Physiotherapy and activities Criteria for progression to next phase
1st phase: Accomodation - Reduce symptomsa
- Normalize ROM og
muscle control
- Education/coaching
- ROM, isometric exercises
- Gait training (no weight-bearing
for two weeks)
- No symptoms during ADL
- Flexion 90°
- Normalized quadriceps
2nd phase: Rehabilitation - Full ROM
- Normalize muscle strength
and joint stability
- Stationary bike cycling




- No symptoms after training
- Equally distributed weight on the lower
limbs during weight-bearing exercises
- Ability to stand on 1 limb on a flat surface
for at least 10 s
3rd phase: Return to activity - Recovery of strength and
neuromuscular control
- Return to activity/sport
- Knee and hip resistance training
- Neuromuscular training
- Cardiovascular training
- Return to activity/sport based on individual
assessment
a Symptoms = pain and swelling
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Hypothesis
Null hypothesis: There is no difference in KOOS QoL
following AM or AD treatment of a symptomatic full
thickness knee cartilage defect less than 2 cm2 24 months
after surgery.
Alternative hypothesis: There is a difference in KOOS
QoL following AM or AD treatment of a symptomatic full
thickness knee cartilage defect less than 2 cm2 24 months
after surgery.
Statistical analysis
Demographic variables will be presented as mean ±
standard deviation (SD) for continuous variables, and
frequencies for categorical variables. The normal distri-
bution of the variables will be tested. Given normal
distribution, the statistical analysis will be performed
using linear mixed models (LMM), including a random
center effect for hospital. The test for the primary object-
ive of comparing KOOS QoL from baseline to 24 months
between the groups can be performed as a post hoc t-test
following the LMM. If the data is not normally distrib-
uted, a non-parametric analysis will be done using the
Mann-Whitney U-test. To evaluate the efficacy of treat-
ment in terms of categorical outcome measures we plan
to use Chi-squared tests. To adjust for possible con-
founders such as age of the patient and severity of the
cartilage lesion, these variables will be included in the
LMM. A p < 0,05 is considered statistically significant. The
statistical analysis will be conducted in collaboration with
a statistician at Unit for Applied Clinical Research at
Norwegian University of Science and Technology, using
SPSS v.22 (SPSS Inc, Chicago, Illinois) and R [49].
Sample size
A difference in KOOS QoL subscore of 8–10 has previ-
ously been shown to be clinically significant [50, 51].
With 80% power comparing the two treatment groups
24 months after surgery by a two-sample t-test, power
analyses is therefore based on detecting a difference of
10. Using a standard deviation (SD) of 18 ([37, 50]
http://www.koos.nu/koosfaq.html), this yields 52 patients
in each group. By adding 10 % due to drop out and loss
to follow-up, a total of 114 patients will be included.
Risk assessments
Participants may find it discomforting and unpleasant
when they are asked about demographic information.
The treatment of choice in this patient category is an
arthroscopic operation, so no additional risks exists in
participating this study. With a frequency < 1 %, these
risks is rare and include arthralgia, joint effusion/swell-
ing deep vein thrombosis (DVT), infection, headache
and nasopharyngitis. Both treatments (AD and AM)
have a risk of failure, and some might be in need of fur-
ther surgery.
If any complication occurs during surgery, postopera-
tive management and rehabilitation, patients will be
examined by the doctor on call and treated according to
clinical guidelines.
Discussion
The treatment of isolated articular cartilage lesions of
the knee is an orthopaedic puzzle, with numerous surgi-
cal techniques. Arthroscopic microfracture treatment
has become the treatment of choice in patients with
knee cartilage defects, but current knowledge is ham-
pered by the lack of well-designed randomized studies
comparing the effect of microfracture with debridement
alone. This study will answer some of the questions
regarding the benefit of AM compared to physical re-
habilitation alone, and the results may help surgeons
improve clinical outcome after articular cartilage injuries
of the knee.
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